title: Palifermin-induced acral erythrodysaesthesia variant in the treatment of acute myeloid leukaemia.
abstract: The recombinant human keratinocyte growth factor, palifermin, offers a potential means of reducing or preventing mucositis in patient undergoing intensive cancer treatments. This case report details the development of acral erythrodysaesthesia in one patient who underwent palifermin treatment prior to high-intensity re-induction chemotherapy for acute myeloid leukaemia.
authors.affiliation: Department of Dermatology, The Alfred Hospital, Prahran, Victoria, Australia. livmilne@gmail.com
authors.forename: Olivia
authors.initials: O
authors.lastname: Milne
authors.forename: Briony
authors.initials: B
authors.lastname: Cutts
authors.forename: Catriona
authors.initials: C
authors.lastname: McLean
authors.forename: Douglas
authors.initials: D
authors.lastname: Gin
mesh_terms: D051523:Fibroblast Growth Factor 7 / Q000009:adverse effects*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D010292:Paresthesia / Q000139:chemically induced* / Q000473:pathology*; D011994:Recombinant Proteins / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D011994:Recombinant Proteins; D051523:Fibroblast Growth Factor 7